Estrogen receptor implications in human pancreatic cancer

Srivani Konduri, Roderich E. Schwarz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The sex steroid estrogen, androgen and progestin hormones all play a functional role in the healthy pancreas. Pancreatic cancer, a highly lethal disease, has a higher prevalence in men compared to women. While these factors may suggest a potential role for sex hormone regulation or dysregulation in pancreatic carcinogenesis, the majority of epidemiological studies have failed to support an association between hormonal factors and pancreatic cancer development. Similarly, hormonal manipulation with the antiestrogen tamoxifen as a therapeutic strategy for pancreatic cancer has been explored clinically, but was met with limited success. Nevertheless, recent studies show that human pancreatic cancers express two subtypes of estrogen receptor (ER), namely ER α and ER β each ER subtype is capable of distinct estrogenic signaling, thus corroborating a role for estrogens in human pancreatic cancer. Furthermore, the ratio of ER β to ER α mRNA level is significantly higher in pancreatic cancer tissues compared to ER-positive as well as ER-negative breast cancers, and several human pancreatic cells have greater ER β protein expression than ER α, suggesting that the ratio of ER α to ER β may be a specific determinant of pancreatic cancer pathology. The focus of this review is to consider the implications of the ER expression on pancreatic cancer responsiveness to selective estrogen receptor modulators (SERMs). The usefulness of androgen and progesterone receptor modulators in pancreatic cancer treatment is also reviewed briefly. All aspects taken together suggest that there is still an opportunity to explore ER signaling as potential target domain for future pancreatic cancer therapy.

Original languageEnglish (US)
Title of host publicationFemale Sex Hormones and Cancers
PublisherNova Science Publishers, Inc.
Pages187-207
Number of pages21
ISBN (Print)9781617286964
StatePublished - 2012

Fingerprint

Pancreatic Neoplasms
Estrogen Receptors
Estrogens
Selective Estrogen Receptor Modulators
Oncology
Estrogen Receptor Modulators
Androgen Receptors
Gonadal Steroid Hormones
Pathology
Progestins
Progesterone Receptors
Tamoxifen
Modulators
Androgens
Epidemiologic Studies
Pancreas
Carcinogenesis
Therapeutics
Steroids
Hormones

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Konduri, S., & Schwarz, R. E. (2012). Estrogen receptor implications in human pancreatic cancer. In Female Sex Hormones and Cancers (pp. 187-207). Nova Science Publishers, Inc..

Estrogen receptor implications in human pancreatic cancer. / Konduri, Srivani; Schwarz, Roderich E.

Female Sex Hormones and Cancers. Nova Science Publishers, Inc., 2012. p. 187-207.

Research output: Chapter in Book/Report/Conference proceedingChapter

Konduri, S & Schwarz, RE 2012, Estrogen receptor implications in human pancreatic cancer. in Female Sex Hormones and Cancers. Nova Science Publishers, Inc., pp. 187-207.
Konduri S, Schwarz RE. Estrogen receptor implications in human pancreatic cancer. In Female Sex Hormones and Cancers. Nova Science Publishers, Inc. 2012. p. 187-207
Konduri, Srivani ; Schwarz, Roderich E. / Estrogen receptor implications in human pancreatic cancer. Female Sex Hormones and Cancers. Nova Science Publishers, Inc., 2012. pp. 187-207
@inbook{b221e283ec80493ab5c10b2843cf0132,
title = "Estrogen receptor implications in human pancreatic cancer",
abstract = "The sex steroid estrogen, androgen and progestin hormones all play a functional role in the healthy pancreas. Pancreatic cancer, a highly lethal disease, has a higher prevalence in men compared to women. While these factors may suggest a potential role for sex hormone regulation or dysregulation in pancreatic carcinogenesis, the majority of epidemiological studies have failed to support an association between hormonal factors and pancreatic cancer development. Similarly, hormonal manipulation with the antiestrogen tamoxifen as a therapeutic strategy for pancreatic cancer has been explored clinically, but was met with limited success. Nevertheless, recent studies show that human pancreatic cancers express two subtypes of estrogen receptor (ER), namely ER α and ER β each ER subtype is capable of distinct estrogenic signaling, thus corroborating a role for estrogens in human pancreatic cancer. Furthermore, the ratio of ER β to ER α mRNA level is significantly higher in pancreatic cancer tissues compared to ER-positive as well as ER-negative breast cancers, and several human pancreatic cells have greater ER β protein expression than ER α, suggesting that the ratio of ER α to ER β may be a specific determinant of pancreatic cancer pathology. The focus of this review is to consider the implications of the ER expression on pancreatic cancer responsiveness to selective estrogen receptor modulators (SERMs). The usefulness of androgen and progesterone receptor modulators in pancreatic cancer treatment is also reviewed briefly. All aspects taken together suggest that there is still an opportunity to explore ER signaling as potential target domain for future pancreatic cancer therapy.",
author = "Srivani Konduri and Schwarz, {Roderich E.}",
year = "2012",
language = "English (US)",
isbn = "9781617286964",
pages = "187--207",
booktitle = "Female Sex Hormones and Cancers",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Estrogen receptor implications in human pancreatic cancer

AU - Konduri, Srivani

AU - Schwarz, Roderich E.

PY - 2012

Y1 - 2012

N2 - The sex steroid estrogen, androgen and progestin hormones all play a functional role in the healthy pancreas. Pancreatic cancer, a highly lethal disease, has a higher prevalence in men compared to women. While these factors may suggest a potential role for sex hormone regulation or dysregulation in pancreatic carcinogenesis, the majority of epidemiological studies have failed to support an association between hormonal factors and pancreatic cancer development. Similarly, hormonal manipulation with the antiestrogen tamoxifen as a therapeutic strategy for pancreatic cancer has been explored clinically, but was met with limited success. Nevertheless, recent studies show that human pancreatic cancers express two subtypes of estrogen receptor (ER), namely ER α and ER β each ER subtype is capable of distinct estrogenic signaling, thus corroborating a role for estrogens in human pancreatic cancer. Furthermore, the ratio of ER β to ER α mRNA level is significantly higher in pancreatic cancer tissues compared to ER-positive as well as ER-negative breast cancers, and several human pancreatic cells have greater ER β protein expression than ER α, suggesting that the ratio of ER α to ER β may be a specific determinant of pancreatic cancer pathology. The focus of this review is to consider the implications of the ER expression on pancreatic cancer responsiveness to selective estrogen receptor modulators (SERMs). The usefulness of androgen and progesterone receptor modulators in pancreatic cancer treatment is also reviewed briefly. All aspects taken together suggest that there is still an opportunity to explore ER signaling as potential target domain for future pancreatic cancer therapy.

AB - The sex steroid estrogen, androgen and progestin hormones all play a functional role in the healthy pancreas. Pancreatic cancer, a highly lethal disease, has a higher prevalence in men compared to women. While these factors may suggest a potential role for sex hormone regulation or dysregulation in pancreatic carcinogenesis, the majority of epidemiological studies have failed to support an association between hormonal factors and pancreatic cancer development. Similarly, hormonal manipulation with the antiestrogen tamoxifen as a therapeutic strategy for pancreatic cancer has been explored clinically, but was met with limited success. Nevertheless, recent studies show that human pancreatic cancers express two subtypes of estrogen receptor (ER), namely ER α and ER β each ER subtype is capable of distinct estrogenic signaling, thus corroborating a role for estrogens in human pancreatic cancer. Furthermore, the ratio of ER β to ER α mRNA level is significantly higher in pancreatic cancer tissues compared to ER-positive as well as ER-negative breast cancers, and several human pancreatic cells have greater ER β protein expression than ER α, suggesting that the ratio of ER α to ER β may be a specific determinant of pancreatic cancer pathology. The focus of this review is to consider the implications of the ER expression on pancreatic cancer responsiveness to selective estrogen receptor modulators (SERMs). The usefulness of androgen and progesterone receptor modulators in pancreatic cancer treatment is also reviewed briefly. All aspects taken together suggest that there is still an opportunity to explore ER signaling as potential target domain for future pancreatic cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84895353109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895353109&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617286964

SP - 187

EP - 207

BT - Female Sex Hormones and Cancers

PB - Nova Science Publishers, Inc.

ER -